In my last post, I described leptin and adiponectin as signals of adipose tissue function, not just biomarkers of fat mass. This post is about what actually moves those signals — and I want to be especially careful here, because the three approaches I'm covering sit at genuinely different levels of evidence. I laid out the reasoning for why that distinction matters in an earlier post on GLP-1s and longevity research: medicine often has to weigh mechanistic plausibility against actual proof, and being honest about which is which matters more here than almost anywhere else on this site.
GLP-1 and GIP therapy: the strongest evidence tier
This is where the human clinical trial data is most robust. A biomarker analysis from the SURMOUNT-1 trial — the major study behind tirzepatide's approval — measured leptin and adiponectin directly at 72 weeks. The results were substantial: leptin fell by roughly 44%, 59%, and 61% at the 5mg, 10mg, and 15mg doses respectively, while adiponectin rose by roughly 21%, 35%, and 48% across those same doses.
Some of this is straightforwardly explained by fat loss itself — less fat tissue generally means less leptin production. But I don't think that's the whole story. GIP receptors are present directly in fat tissue, and GLP-1/GIP signaling appears to alter how fat cells themselves function, not just how much fat tissue exists. That's part of why metabolic improvement on these medications can look more substantial than weight loss numbers alone would predict — the adipose tissue that remains may be functioning in a healthier way, not just occupying less space.
This tier of evidence — large randomized trials, direct biomarker measurement, dose-dependent effects — is the strongest kind available in this space, and it's the same standard I hold the rest of GLP-1 therapy's claims to throughout this site.
Tesamorelin: real evidence, a different mechanism
Tesamorelin is a growth-hormone-releasing hormone analog, FDA-approved specifically for reducing visceral fat in a defined patient population. Its trial data is genuinely strong on its primary outcome — visceral fat reduction of roughly 15% over 26 weeks in the pivotal trials, a real and well-replicated effect.
Where it gets more nuanced is the adiponectin question specifically. It would be easy to describe tesamorelin as an "adiponectin drug," but the actual data doesn't support that simple framing. What the research shows is more specific: patients who achieve a meaningful reduction in visceral fat on tesamorelin — roughly 8% or more — see significant improvements in adiponectin and other metabolic markers, while patients who don't achieve that threshold of fat reduction don't see the same benefit. In other words, the adiponectin improvement tracks with how much visceral fat actually comes off, rather than being a direct, independent effect of the medication itself. I'd classify tesamorelin as a visceral-fat-remodeling therapy whose adipokine benefits are downstream of that primary effect, not a direct adipokine-targeting treatment in its own right.
MOTS-c: a genuinely interesting mechanism, not yet human-proven
MOTS-c is a peptide produced by mitochondria, which I introduced in an earlier post on exercise mimetics. There's real, published research — in mice and cultured muscle cells — showing a bidirectional relationship between MOTS-c and adiponectin: adiponectin increases MOTS-c production in skeletal muscle through a specific signaling pathway, and administering MOTS-c in turn increases adiponectin levels. Conceptually, this connects muscle metabolism directly to adipose signaling, which is a genuinely elegant piece of biology.
I want to be exact about what this is and isn't. This is compelling mechanistic and preclinical research — animal and cell-culture studies, not human clinical trials demonstrating a therapeutic adiponectin effect. It belongs firmly in the "mechanistically plausible, not yet proven" category I described in the GLP-1 longevity post. That doesn't make it uninteresting — mitochondrial-derived peptides are a genuinely active area of research, and this pathway is one of the more mechanistically clean stories I've come across. But it's not something I'd currently place in the same evidence category as GLP-1 therapy or even tesamorelin.
Why I'm laying these three out side by side
Three different approaches, three different evidence tiers: strong randomized human trial data for GLP-1 therapy's effect on both leptin and adiponectin; real human trial data for tesamorelin, but with a more specific, fat-reduction-dependent relationship to adiponectin than a simple direct effect; and compelling mechanistic biology for MOTS-c that hasn't yet been tested in humans for this purpose.
This is exactly the kind of distinction I think matters most when peptide therapy comes up in a comprehensive care plan. None of these three approaches are interchangeable, and treating them as equally proven would be dishonest. What they share is biological plausibility rooted in the same underlying signaling network — leptin, adiponectin, visceral fat, and metabolic function are all connected, which is why interventions that work through different specific mechanisms can still converge on related outcomes. But "connected mechanism" and "equivalent evidence" are not the same claim, and I don't want to blur them.
What I'd want you to take from this
If leptin and adiponectin come up in your own care — whether through lab work, a conversation about GLP-1 therapy, or interest in more exploratory peptide research — I'd encourage the same question I've encouraged throughout this site: not just "does this affect the marker," but "how strong is the evidence that it does, and what does that evidence actually consist of." GLP-1 therapy's effects here are about as well-documented as anything in this field gets. The other approaches I've covered here are worth knowing about, worth watching, and in some cases worth discussing with your provider — but they're not there yet, and I'd rather tell you that directly than let the biology sound more settled than it is.
Curious how your own adipose signaling markers might respond to different treatment approaches?
No spam. Occasional new posts and updates from The Center for Metabolic Health.
Medical disclaimer: This content is provided for general educational and informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any condition, and it does not create a physician-patient relationship. Every patient's medical history, health status, and treatment needs are different. Always consult your own physician or qualified healthcare provider before starting, stopping, or changing any medication or treatment, and before making any decisions based on information found here. If you are experiencing a medical emergency, call 911 or go to your nearest emergency room.